4D-710 — Competitive Intelligence Brief

4D-710 (4D-710) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy. Area: Cystic Fibrosis.

phase 2 Gene therapy CFTR gene Cystic Fibrosis Biologic

Target snapshot

4D-710 (4D-710) — 4D Molecular Therapeutics. 4D-710 is a gene therapy that uses an adeno-associated virus to deliver a functional copy of the CFTR gene to the lungs, correcting the underlying genetic defect in cystic fibrosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
4D-710 TARGET	4D-710	4D Molecular Therapeutics	phase 2	Gene therapy	CFTR gene
voretigene neparvovec-rzyl	voretigene neparvovec-rzyl	Spark Therapeutics, Inc.	marketed	Gene therapy	RPE65 gene
Onasemnogene Abeparvovec-xioi	Onasemnogene Abeparvovec-xioi	Novartis Gene Therapies	marketed	Gene therapy	SMN1 gene
Onasemnogene Abeparvovec-brve	Onasemnogene Abeparvovec-brve	Novartis Pharmaceuticals	marketed	Gene Therapy	SMN1 gene
p53 with chemotherapy	p53 with chemotherapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; recombinant adenovirus vector	p53 (tumor suppressor protein)
p53 gene therapy	p53 gene therapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy	p53 (tumor suppressor protein)
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy class)

1. Spark Therapeutics, Inc. · 4 drugs in this class
2. MeiraGTx UK II Ltd · 3 drugs in this class
3. Novartis Gene Therapies · 2 drugs in this class
4. Kolon TissueGene, Inc. · 2 drugs in this class
5. Krystal Biotech, Inc. · 2 drugs in this class
6. Abeona Therapeutics, Inc · 2 drugs in this class
7. Larimar Therapeutics, Inc. · 1 drug in this class
8. 4D Molecular Therapeutics · 1 drug in this class
9. Medeor Therapeutics, Inc. · 1 drug in this class
10. MeiraGTx, LLC · 1 drug in this class